SpringWorks Therapeutics Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Springworks Therapeutics, Inc. |
| Form Type | 10-Q |
| Filed Date | May 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, biotechnology, financials
TL;DR
**SpringWorks Q1 2025 10-Q filed. Financials and operations update.**
AI Summary
SpringWorks Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, focused on biological products, is based in Stamford, CT, and operates under the SEC file number 001-39044. This filing details financial information and business operations for the first quarter of 2025.
Why It Matters
This filing provides investors and analysts with the latest financial performance and operational updates for SpringWorks Therapeutics, crucial for assessing the company's current standing and future prospects in the biotechnology sector.
Risk Assessment
Risk Level: medium — As a biotechnology company, SpringWorks Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-05-09 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- SpringWorks Therapeutics, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250509 (date) — Filing date of the report
- Stamford, CT (location) — Company's business and mailing address
- 001-39044 (other) — SEC file number
FAQ
What is the primary business of SpringWorks Therapeutics, Inc.?
SpringWorks Therapeutics, Inc. is primarily involved in the biological products sector, specifically focusing on products without diagnostic substances, as indicated by SIC code 2836.
For which fiscal period is this 10-Q report filed?
This 10-Q report is filed for the fiscal period ending March 31, 2025.
When was this 10-Q filing submitted to the SEC?
The filing was submitted on May 9, 2025.
What is the company's principal executive office location?
The company's principal executive office is located at 100 Washington Boulevard, Stamford, CT 06902.
What is the SEC file number associated with SpringWorks Therapeutics, Inc.?
The SEC file number for SpringWorks Therapeutics, Inc. is 001-39044.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding SpringWorks Therapeutics, Inc..